Should gentamicin resistant aac(6')-Ib be renamed to aac(6')-IId?

[feldgard]

This is prompted by a question to NCBI:

"This protein is AAC(6')-IId and should not be called AAC(6')-Ib4. The protein contains a Leu to Ser change at aa 102 (DQLLA->DQSLA) that changes the spectrum from amikacin resistant, gentamicin sensitive to gentamicin resistant, amikacin sensitive i.e. AAC(6')-II. Even though the gene is a point mutant and in molecular terms is very close to aac(6')-Ib, the phenotype is more important and the gene should be named accordingly. There are several other variants with different initiation codons (some real, some imaginary) but anything with DQSLA is also AAC(6')-IId."

The issue is that based on its phenotype, it ideally should be called aac(6')-IId (our contact is correct). The problem we have run into is that the literature, including several reviews, treats aac(6')-Ib as a de facto homology group, even though that contravenes the nomenclature system (the -I and -II denote distinct resistance phenotypes). This, unfortunately, forces us to choose between 'breaking the nomenclature' and 'breaking the literature.'

Any thoughts on whether we should change the gentamicin resistance conferring aac(6')-Ib's to aac(6')-IId? Thanks.